Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds. It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014, becoming the first approved therapy against PD-1. In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers.
Pembrolizumab is indicated for the following conditions:
For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.
Harris Health System - Smith Clinic, Houston, Texas, United States
O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
James Lind Centro de Investigación del Cáncer ( Site 0102), Temuco, Araucania, Chile
FALP-UIDO ( Site 0101), Santiago, Region M. De Santiago, Chile
Cancercare Rondebosch Oncology-Clinical trials ( Site 0055), Rondebosch, Western Cape, South Africa
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Stanford Cancer Center ( Site 0023), Palo Alto, California, United States
Northwestern Memorial Hospital ( Site 0002), Chicago, Illinois, United States
Texas Oncology-Plano East ( Site 0020), Plano, Texas, United States
Memorial Sloan Kettering - Bergen ( Site 1025), Montvale, New Jersey, United States
Memorial Sloan Kettering - Monmouth ( Site 1022), Middletown, New Jersey, United States
Memorial Sloan Kettering - Basking Ridge ( Site 1023), Basking Ridge, New Jersey, United States
National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit, Detroit, Michigan, United States
Florida Cancer Specialists, Altamonte Springs, Florida, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China
Mayo Clinic, Jacksonville, Florida, United States
UZ Antwerpen, Edegem, Belgium
UZ Gent, Ghent, Belgium
Queen Mary Hospital, Hong Kong, Hong Kong
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.